GlycoFlux™ Human SIGLEC12 Overexpression Raji Cell Line (CAT#: GLJF-0925-JF1041)

Description	GlycoFlux™ human SIGLEC12 overexpression Raji cell line is a stable cell line engineered to overexpress SIGLEC12, a CD33-like inhibitory receptor with ITIM and SLAM-like motifs that recruits SHP1/2 upon phosphorylation. It negatively regulates macrophage activation and is clustered with related genes at 19q13.4. This model supports studies of macrophage signaling, inhibitory lectins, and immune regulation.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Lymphoblast-like, suspension growth
Passage Ratio	1:2~1:4
Cell Line	Raji
Primary Disease	Burkitt's lymphoma
Lineage	B lymphocyte (B cell)
Lineage Subtype	Mature B cell, widely used in EBV-related studies

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	FBS & RPMI
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	SIGLEC12
Full Name	Sialic Acid Binding Ig Like Lectin 12
Alternative Name	S2V; SLG; SIGLECL1; Siglec-XII; Sialic Acid Binding Ig Like Lectin
Location	19q13.41
Gene ID	89858
Summary	Sialic acid-binding immunoglobulin-like lectins (SIGLECs) are a family of cell surface proteins belonging to the immunoglobulin superfamily. They mediate protein-carbohydrate interactions by selectively binding to different sialic acid moieties present on glycolipids and glycoproteins. This gene encodes a member of the SIGLEC3-like subfamily of SIGLECs. Members of this subfamily are characterized by an extracellular V-set immunoglobulin-like domain followed by two C2-set immunoglobulin-like domains, and the cytoplasmic tyrosine-based motifs ITIM and SLAM-like. The encoded protein, upon tyrosine phosphorylation, has been shown to recruit the Src homology 2 domain-containing protein-tyrosine phosphatases SHP1 and SHP2. It has been suggested that the protein is involved in the negative regulation of macrophage signaling by functioning as an inhibitory receptor. This gene is located in a cluster with other SIGLEC3-like genes on 19q13.4. Alternative splicing results in multiple transcript variants.